Renaissance Technologies LLC Decreases Stake in Synlogic, Inc. (NASDAQ:SYBX)

Renaissance Technologies LLC decreased its holdings in Synlogic, Inc. (NASDAQ:SYBX) by 69.0% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 22,310 shares of the biotechnology company’s stock after selling 49,618 shares during the quarter. Renaissance Technologies LLC owned about 0.19% of Synlogic worth $31,000 as of its most recent filing with the SEC.

Synlogic Stock Up 1.9 %

Shares of NASDAQ SYBX opened at $1.14 on Friday. The stock has a market capitalization of $13.35 million, a price-to-earnings ratio of -0.27 and a beta of 0.56. Synlogic, Inc. has a 52 week low of $0.90 and a 52 week high of $1.88. The firm has a 50-day moving average price of $1.17 and a 200 day moving average price of $1.33.

Synlogic (NASDAQ:SYBX) last posted its quarterly earnings results on Thursday, March 6th. The biotechnology company reported ($0.06) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.04. Equities research analysts expect that Synlogic, Inc. will post -2.71 EPS for the current fiscal year.

About Synlogic

Synlogic, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic diseases in the United States. Its pipeline include SYNB1618, an orally administered, non-systemically absorbed drug candidate to treat phenylketonuria; SYNB1934, an orally administered, non-systemically absorbed drug candidate, which is in Phase III clinical trial to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate, which is in Phase I clinical to treat homocystinuria; SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase II clinical trial for the treatment of enteric hyperoxaluria; and SYNB2081 to lower uric acid for the potential treatment of gout.